HR 2913, the Ukraine Support Act, provides comprehensive U.S. support for Ukraine in response to Russia's invasion. The bill authorizes security assistance including lend-lease authority for military equipment, establishes a Ukraine Reconstruction Trust Fund for economic recovery, and imposes new sanctions targeting Russian financial institutions, oil companies, and government officials. It also includes provisions to counter Russian disinformation, support Radio Free Europe, and address the kidnapping of Ukrainian children. The legislation directly affects U.S. foreign policy, Ukraine's defense capabilities, and Russia's access to international financial systems. The act aims to strengthen Ukraine's sovereignty while holding Russia accountable for its actions.
The IBOGAINE Act aims to accelerate the development and approval of ibogaine and similar compounds for treating addiction, trauma, and serious mental illnesses by modifying federal drug laws. It creates a new voucher system that grants sponsors of breakthrough mental health drugs priority review by the FDA, while also establishing special registration rules to allow physicians to legally administer Schedule I substances to eligible patients under the "right to try" law. The legislation further directs the Department of Veterans Affairs to create a dedicated senior official and workforce plan for emerging therapies, mandates timely rescheduling of ibogaine from Schedule I to Schedule II, and requires federal agencies to share clinical trial data to speed up the approval process.
The Save MEDICARE Act of 2026 aims to improve the Medicare Advantage program by starting in 2028 with several changes to how health plans are paid and monitored. It requires the government to exclude diagnoses from chart reviews when calculating payments to prevent plans from inflating costs based on questionable data. The bill also speeds up audits and appeals to ensure faster resolution of coding disputes and introduces a new penalty system to recover overpayments from plans. Additionally, the law allows states to enforce Medicare rules within their borders and bans financial incentives for doctors based on how they code patient records. Finally, it establishes a mechanism for the Department of Veterans Affairs to recover costs when Medicare Advantage plans cover care that should have been paid for by the VA.
This resolution honors the life and legacy of the late Senator Lindsey Olin Graham from South Carolina. It formally acknowledges his extensive career in the military, state government, and Congress, noting his service as a Senator and his roles as Chairman of the Judiciary and Budget committees. The Senate expresses its sorrow over his death and requests that this tribute be shared with the House of Representatives and Graham's family.
This resolution expresses the House of Representatives' support for maintaining equity, diversity, and inclusion in federally funded health research to improve scientific quality and patient outcomes. It opposes proposed administrative rules that would allow political appointees to override peer reviews, restrict international collaborations, and ban funding for studies on diversity and health disparities. The text highlights historical data showing that excluding women and people of color from research has led to medical gaps, such as inaccurate diagnostic tools for Black patients and delayed diagnoses for women with heart disease. Ultimately, the bill urges the administration to preserve the current science-based peer review system and remove barriers that prevent underserved communities from benefiting from medical advancements.
The Cannabis Administration and Opportunity Act fundamentally changes federal law by removing marijuana from the Controlled Substances Act, effectively decriminalizing it at the federal level and allowing states to regulate their own cannabis markets without federal interference. To manage this new landscape, the bill creates a new federal agency called the Alcohol, Tobacco, and Cannabis Tax and Trade Bureau to oversee licensing, collect taxes, and prevent illicit trade, while also establishing a new Center for Cannabis Products within the FDA to regulate safety and labeling. The legislation includes significant restorative justice measures, such as automatically expunging federal cannabis convictions and prohibiting discrimination against individuals with such records in areas like immigration, security clearances, and access to federal benefits. Additionally, the bill provides billions of dollars in funding to support research into the health effects of cannabis, expand access to financial services for legitimate cannabis businesses, and assist communities and individuals harmed by past prohibition enforcement.
The Clean Water Allotment Modernization Act of 2026 updates how federal funding for water pollution control is distributed among states, Indian tribes, and U.S. territories. It requires the Environmental Protection Agency to set aside specific portions of funds for oversight and tribes before calculating state shares, while also introducing a new formula that allocates money based on watershed needs, population size, and poverty levels. The bill includes safeguards to prevent funding amounts for any single state from changing drastically from one year to the next and allows states to use a small percentage of their grants to conduct the necessary assessments for this new formula. Additionally, the legislation clarifies that these changes do not affect existing infrastructure funds and expands the allowable uses of capitalization grants to include technical assistance and survey activities.
The Biotechnology Diplomacy Leadership Act of 2026 directs the Secretary of State to appoint a Senior Biotechnology Official within 90 days to lead U.S. diplomatic efforts in this field. This official must have expertise in biotechnology, international relations, and national security, and will work across federal agencies to coordinate global partnerships and policy initiatives. Their main duties include representing the State Department in international forums, securing supply chains, facilitating data-sharing agreements, and supporting research and capacity-building programs in partner nations. The official will also provide regular reports to the Secretary of State on the progress and outcomes of these diplomatic activities.
The Health Claim Denial Transparency Act requires group health plans to include detailed data in their annual reports, specifically detailing the number of claims submitted, approved, denied, and appealed. This reporting covers various claim types, including prescription drugs, mental health services, cancer treatments, and those processed using artificial intelligence, while also specifying the reasons for denials such as lack of prior authorization or medical necessity. The law applies to plans with fewer than 100 participants and includes an exception for small plans that handle very few specific types of claims to avoid excessive administrative burdens. By mandating this disclosure, the bill aims to increase visibility into how health plans process and reject medical benefit requests.
Orlin's Law requires immigration officials to identify detained parents and prioritize family unity by limiting detention when possible. The bill mandates that parents be allowed to make free calls and visits with their children, participate in family court proceedings, and access necessary documents to care for their dependents. It also establishes a new office within U.S. Immigration and Customs Enforcement to coordinate these protections and provides for community-based alternatives to detention. Additionally, the law creates a presumption that parental rights remain intact even if a child is separated from a detained parent and outlines specific steps to facilitate reunification upon removal.
The Family Grocery and Farmer Relief Act aims to break up the highly concentrated meatpacking industry by forcing major companies to divest assets and stop operating in multiple meat categories simultaneously. The Federal Trade Commission is authorized to order these divestitures if market concentration remains too high or if a single firm controls a large share of beef processing, with a specific goal of transferring assets to farmers' cooperatives and small businesses. Additionally, the bill mandates that foreign-owned meatpacking firms divest their U.S. operations and prohibits companies from acquiring new assets in lines of protein they do not already process. To support these changes, the legislation provides funding for new competitors and requires the FTC to actively enforce these rules against firms that fail to comply.
The TRUTH in Coverage Act of 2026 requires group health plans and health insurance issuers that cover gender-affirming procedures to also cover medical services intended to treat physical and psychological complications resulting from those procedures. This mandate applies regardless of whether the original gender-affirming treatment was covered by the plan and ensures that any required follow-up care faces the same cost-sharing rules and limitations as standard medical benefits. The bill defines "sex-rejecting procedures" broadly to include hormone therapy, surgeries, and puberty blockers, while explicitly excluding treatments for intersex conditions, life-threatening emergencies, and standard puberty suppression for early puberty. These provisions would take effect for plan years beginning on or after January 1, 2027, affecting individuals with access to employer-sponsored or individual health insurance.
